For millions of Americans, the cost of health care remains one of the most pressing financial challenges they face. While inflation and everyday expenses continue to strain household budgets, many families report that medical costs rank among their biggest concerns. Few issues illustrate that reality more clearly than the price of insulin.
Nearly 8.4 million Americans rely on insulin to manage diabetes, and unlike many other expenses, it is not something patients can simply reduce when money gets tight. For people living with Type 1 diabetes, insulin is essential for survival. Yet studies have shown that many patients have resorted to rationing their medication because of cost, creating serious health risks and potentially life-threatening consequences.
The burden extends beyond those without insurance. Even families with coverage increasingly report struggling with rising premiums, deductibles, and out-of-pocket expenses. As a result, many Americans find themselves facing difficult financial decisions involving medications they need every day.
Recent policy changes have demonstrated that insulin costs can be reduced. The Inflation Reduction Act capped monthly insulin expenses at $35 for Medicare beneficiaries, providing relief for millions of seniors who depend on the medication. Data from Johns Hopkins University found that the share of Medicare patients paying $35 or less per month for insulin increased substantially after the policy took effect, while average out-of-pocket costs fell significantly.
Researchers have also reported improvements beyond simple affordability. Lower costs have been associated with reductions in emergency room visits and hospitalizations related to diabetes complications among Medicare recipients.
However, those protections currently apply only to Medicare beneficiaries. Millions of Americans with employer-sponsored insurance or no insurance at all remain vulnerable to significantly higher insulin costs.
Supporters of expanding the cap argue that affordability should not depend on a person’s age or insurance category. They point to examples of families paying hundreds of dollars each month for insulin despite having health coverage, raising questions about why access to a decades-old medication remains financially challenging for so many Americans.
That debate has produced a bipartisan response in the Senate. Senators Bill Cassidy, Susan Collins, Raphael Warnock, and John Kennedy recently introduced the INSULIN Act, legislation that would extend a $35 monthly insulin cap to Americans with employer-sponsored health plans while creating additional pathways for uninsured patients to obtain lower-cost insulin.
Notably, the proposal has attracted support from lawmakers across the political spectrum. Backers argue that insulin affordability represents one of the rare healthcare issues capable of generating broad agreement among Republicans, Democrats, and independent voters alike.
Senator Cassidy has also spoken about the issue from personal experience. His granddaughter, Elle, was diagnosed with Type 1 diabetes as a child, giving his family firsthand insight into the daily challenges faced by millions of Americans managing the disease.
As Congress continues debating healthcare costs, insulin remains one area where lawmakers can point to existing evidence showing that targeted reforms have produced measurable results. Supporters of the INSULIN Act argue that extending those protections beyond Medicare would help ensure that access to lifesaving medication is determined by medical need rather than financial circumstances.
